MCID: SJG008
MIFTS: 54

Sjogren Syndrome

Categories: Rare diseases, Immune diseases, Bone diseases

Aliases & Classifications for Sjogren Syndrome

MalaCards integrated aliases for Sjogren Syndrome:

Name: Sjogren Syndrome 57 12 53 25
Sjogren's Syndrome 12 25 37 43 44 15 73
Sicca Syndrome 57 12 53 25 73
Keratoconjunctivitis Sicca 25 73
Sjogren-Gougerot Syndrome 53 25
Keratoconjunctivitis Sicca-Xerostomia 25
Secreto-Inhibitor-Xerodermostenosis 25
Dacryosialoadenopathia Atrophicans 25
Gougerot-Houwer-Sjogren Syndrome 25
Gougerot-Sjogren Syndrome 25
Sjögren's Syndrome 54
Dry Eye Syndromes 73
Sjogrens Syndrome 55
Xerodermosteosis 12

Characteristics:

OMIM:

57
Inheritance:
autosomal recessive


HPO:

32
sjogren syndrome:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Sjogren Syndrome

MedlinePlus : 43 Sjogren's syndrome is an autoimmune disease. This means that your immune system attacks parts of your own body by mistake. In Sjogren's syndrome, it attacks the glands that make tears and saliva. This causes a dry mouth and dry eyes. You may have dryness in other places that need moisture, such as your nose, throat, and skin. Sjogren's can also affect other parts of the body, including your joints, lungs, kidneys, blood vessels, digestive organs, and nerves. Most people with Sjogren's syndrome are women. It usually starts after age 40. It is sometimes linked to other diseases such as rheumatoid arthritis and lupus. To make a diagnosis, doctors may use a medical history, physical exam, certain eye and mouth tests, blood tests, and biopsies. Treatment focuses on relieving symptoms. It can differ for each person; it depends on what parts of the body are affected. It may include artificial tears for dye eyes and sucking on sugar-free candy or drinking water often for a dry mouth. Medicines may help with severe symptoms. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Sjogren Syndrome, also known as sjogren's syndrome, is related to aplasia of lacrimal and salivary glands and sialadenitis, and has symptoms including dryness of eye, eye manifestations and back pain. An important gene associated with Sjogren Syndrome is LINC02384 (Long Intergenic Non-Protein Coding RNA 2384
It was significantly upregulated in pSS
Dysfunction Pattern: Expression), and among its related pathways/superpathways are Toll-like receptor signaling pathway and Jak-STAT signaling pathway. The drugs Calcium Carbonate and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and skin, and related phenotypes are xerostomia and keratoconjunctivitis sicca

Disease Ontology : 12 A hypersensitivity reaction type II disease that involves attack of immune cells which destroy the exocrine glands that produce tears and saliva.

NIH Rare Diseases : 53 Sjögren syndrome is an autoimmune disorder in which immune cells attack and destroy the glands that produce tears and saliva. Sjögren syndrome is also associated with rheumatic disorders such as rheumatoid arthritis or systemic lupus erythematosus. The hallmark symptoms of Sjögren syndrome are dry mouth and dry eyes. In addition, Sjogren syndrome may cause skin, nose, and vaginal dryness. It also may affect other organs of the body including the kidneys, blood vessels, lungs, liver, pancreas, and brain. Treatment focuses on the symptoms in each person and may include moisture replacement therapies, nonsteroidal anti-inflammatory drugs and, in severe cases, corticosteroids or immunosuppressive drugs.

OMIM : 57 Sjogren syndrome is an autoimmune disease that mainly affects the exocrine glands. It is clinically characterized by keratoconjunctivitis sicca and xerostomia (Goransson et al., 2006). See 200400 for association of Sjogren syndrome with achalasia in sisters. (270150)

Wikipedia : 76 Sjögren syndrome (SjS, SS) is a long-term autoimmune disease in which the moisture-producing glands of... more...

Related Diseases for Sjogren Syndrome

Diseases in the Sjogren Syndrome family:

Sjogren's Syndrome, Juvenile, Secondary to Autoimmune Disease Primary Sjögren Syndrome

Diseases related to Sjogren Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Related Disease Score Top Affiliating Genes
1 aplasia of lacrimal and salivary glands 31.7 CHRM3 HSPG2 SPTAN1
2 sialadenitis 30.0 HSPG2 TNFSF13B TRIM21
3 lupus erythematosus 29.7 APOH SSB TNFSF4 TRIM21 TROVE2
4 primary sjögren syndrome 29.2 B2M CD79A CHRM3 HSPG2 SPTAN1 TNFSF13B
5 systemic lupus erythematosus 28.2 APOH CD79A FASLG SSB TNFSF13B TNFSF4
6 keratoconjunctivitis sicca 12.7
7 marinesco-sjogren syndrome 12.4
8 tenorio syndrome 11.0
9 congenital cataracts, facial dysmorphism, and neuropathy 10.9
10 autoimmune disease 6 10.9
11 systemic scleroderma 10.9
12 igg4-related dacryoadenitis and sialadenitis 10.9
13 neonatal lupus erythematosus 10.8 SPTAN1 TRIM21
14 transient neonatal thrombocytopenia 10.8 CD79A TRIM21
15 transient neonatal neutropenia 10.8 CD79A TRIM21
16 third-degree atrioventricular block 10.7 TRIM21 TROVE2
17 heart block, congenital 10.7 TRIM21 TROVE2
18 xerophthalmia 10.6 HSPG2 TRIM21
19 chronic graft versus host disease 10.6 CD79A TNFSF13B
20 rheumatic disease 10.5 APOH SSB TRIM21
21 sclerosing keratitis 10.5 B2M CD79A
22 cogan syndrome 10.5 CD79A TRIM21 TROVE2
23 orthostatic proteinuria 10.4 B2M CD79A
24 prothrombin deficiency 10.4 APOH TNFSF13B
25 hyperglobulinemic purpura 10.4 CD79A HSPG2 TRIM21
26 diffuse glomerulonephritis 10.4 B2M CD79A
27 primary thrombocytopenia 10.4 CD79A TNFSF13B
28 danubian endemic familial nephropathy 10.4 B2M CD79A
29 exanthem 10.3 CD79A HSPG2 TRIM21
30 non-secretory myeloma 10.3 B2M CD79A
31 connective tissue disease 10.3 APOH SSB TNFSF13B
32 vasculitis 10.3 APOH CD79A TNFSF13B
33 small intestine lymphoma 10.3 B2M CD79A SIL1
34 amyloid tumor 10.3 B2M CD79A
35 syphilis 10.2 APOH B2M CD79A
36 pyelitis 10.2 B2M CD79A CHRM3
37 immune system disease 10.1 APOH CD79A TNFSF13B TRIM21
38 hypersensitivity reaction disease 9.9 APOH CD79A SSB TNFSF13B TRIM21
39 functional colonic disease 9.9 B2M HSPG2
40 cataract 9.8
41 behcet syndrome 9.8 APOH CD79A HSPG2
42 salivary gland disease 9.8 CD79A HSPG2 TNFSF13B TRIM21 TROVE2
43 monoclonal gammopathy of uncertain significance 9.8 B2M CD79A
44 rheumatoid arthritis 9.7
45 arthritis 9.7
46 hepatitis 9.7
47 renal tubular acidosis 9.7
48 myopathy 9.7
49 amyloidosis 9.7
50 multiple sclerosis 9.6

Comorbidity relations with Sjogren Syndrome via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hypothyroidism Ichthyosis Vulgaris
Osteoporosis Postinflammatory Pulmonary Fibrosis
Rheumatoid Arthritis Systemic Lupus Erythematosus

Graphical network of the top 20 diseases related to Sjogren Syndrome:



Diseases related to Sjogren Syndrome

Symptoms & Phenotypes for Sjogren Syndrome

Symptoms via clinical synopsis from OMIM:

57
Head And Neck Mouth:
xerostomia

Immunology:
autoimmune disease

Head And Neck Eyes:
xerophthalmia, more severe in men

Skeletal:
rheumatoid arthritis

Genitourinary Kidneys:
interstitial nephritis


Clinical features from OMIM:

270150

Human phenotypes related to Sjogren Syndrome:

32 (show all 6)
# Description HPO Frequency HPO Source Accession
1 xerostomia 32 HP:0000217
2 keratoconjunctivitis sicca 32 HP:0001097
3 rheumatoid arthritis 32 HP:0001370
4 abnormality of metabolism/homeostasis 32 HP:0001939
5 tubulointerstitial nephritis 32 HP:0001970
6 autoimmunity 32 HP:0002960

UMLS symptoms related to Sjogren Syndrome:


dryness of eye, eye manifestations, back pain, muscle cramp, sciatica

Drugs & Therapeutics for Sjogren Syndrome

Drugs for Sjogren Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3 50-18-0, 6055-19-2 2907
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 299-42-3 9294
6
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-82-4 7028
7
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Not Applicable 9004-61-9 53477741
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2 50-02-2 5743
9
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
10
Pilocarpine Approved, Investigational Phase 4 54-71-7, 92-13-7 5910
11
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4,Phase 2 53-43-0 9860744
12
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
13 Gallopamil Investigational Phase 4 16662-47-8
14 Antacids Phase 4,Phase 2,Not Applicable
15 Antifungal Agents Phase 4,Phase 2
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Anti-Inflammatory Agents Phase 4,Phase 2,Not Applicable
18 Antineoplastic Agents, Hormonal Phase 4,Phase 2
19 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Anti-Ulcer Agents Phase 4,Phase 2,Not Applicable
21 Calcineurin Inhibitors Phase 4,Phase 2
22 Calcium, Dietary Phase 4,Not Applicable
23 Cyclosporins Phase 4,Phase 2,Not Applicable
24 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Gastrointestinal Agents Phase 4,Phase 2,Phase 1,Not Applicable
26 glucocorticoids Phase 4,Phase 2
27 Hormone Antagonists Phase 4,Phase 2
28 Hormones Phase 4,Phase 2
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2
30 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
31 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2
32 Vaccines Phase 4
33 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Nasal Decongestants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
42 Viscosupplements Phase 4,Phase 3
43 Antiemetics Phase 4,Phase 2
44 BB 1101 Phase 4,Phase 2
45 Dexamethasone acetate Phase 4,Phase 2 1177-87-3
46 HIV Protease Inhibitors Phase 4,Phase 2
47
protease inhibitors Phase 4,Phase 2
48 Carbopol 940 Phase 4,Not Applicable
49 Cathartics Phase 4
50 Laxatives Phase 4

Interventional clinical trials:

(show top 50) (show all 178)
# Name Status NCT ID Phase Drugs
1 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
2 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Quality of Life and Sjögren Syndrome Completed NCT03578900 Phase 4 Xeros;Citric Acid based Mouthwash
5 Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention Completed NCT00631358 Phase 4 Maxidex
6 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
7 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
8 A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment Completed NCT00438048 Phase 4 Artificial Saliva
9 A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Completed NCT02049112 Phase 4
10 Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome Recruiting NCT03319420 Phase 4 LO2A eye drops;Systane Ultra UD
11 Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Recruiting NCT03540823 Phase 4
12 Effect of Pilocarpine in Patients With Xerostomia Recruiting NCT02982577 Phase 4 Pilocarpine
13 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
14 Efficacy of Tocilizumab in Primary Sjögren's Syndrome. Unknown status NCT01782235 Phase 2, Phase 3 Tocilizumab;Placebo
15 Treatment of Salivary Gland Hypofunction With Neuro- Electrostimulation Unknown status NCT01174329 Phase 2, Phase 3
16 Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye Unknown status NCT02257957 Phase 3 PRP injection;Standard care Hyaluronic acid eye drops
17 WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
18 Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome Completed NCT00632866 Phase 3 Hydroxychloroquine;Placebo
19 Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome Completed NCT01601028 Phase 3 Hydroxychloroquine;Placebo
20 A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome Completed NCT02503163 Phase 3 KCT-0809 ophthalmic solution
21 A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome Completed NCT02503189 Phase 3 KCT-0809 ophthalmic solution;Placebo
22 Tolerance and Efficacy of Rituximab in Sjogren's Disease Completed NCT00740948 Phase 2, Phase 3 Rituximab (mabthera) Injection;Placebo: NaCl 0.9% or Glucose 5%
23 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
24 Preventive IVIG Therapy for Congenital Heart Block Completed NCT00460928 Phase 2, Phase 3 intravenous immune globulin (IVIG)
25 Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome Recruiting NCT02067910 Phase 3 Abatacept SC
26 A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS) Recruiting NCT03445650 Phase 3 ADX-102 1% Topical Dermal Cream;Vehicle of ADX-102 Topical Dermal Cream
27 A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome Active, not recruiting NCT02915159 Phase 3
28 Treating Dry Eyes and Corneal Ulcers With Fingerprick Autologous Blood Enrolling by invitation NCT02153515 Phase 3
29 Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Not yet recruiting NCT03436576 Phase 3 Autologous Serum 20%;Autologous Serum 50%
30 An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome Terminated NCT02503176 Phase 3 KCT-0809 ophthalmic solution
31 Effect of Saliva Substitutes on Dental Hard Tissues in Situ Terminated NCT01165970 Phase 2, Phase 3 Glandosane
32 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3 N-Acetylcysteine
33 Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS) Unknown status NCT00953485 Phase 1, Phase 2
34 Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome Unknown status NCT02110446 Phase 2 SS-1;Placebo
35 Acupuncture for Primary Sjögren Syndrome Unknown status NCT02691377 Phase 2
36 Low Dose Cyclosporin A in Primary Sjögren Syndrome Completed NCT01693393 Phase 2 Cyclosporine A
37 PD of VAY736 in Patients With Primary Sjögren's Syndrome Completed NCT02149420 Phase 2 VAY736;Placebo
38 Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome Completed NCT02775916 Phase 2 CDZ173;Placebo
39 A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome Completed NCT02701985 Phase 2 Placebo;RO5459072
40 A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome Completed NCT02464319 Phase 2 hrIL-2 active;hrIL-2 placebo
41 A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome Completed NCT00852839 Phase 2 Placebo;552-02
42 Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome Completed NCT01008982 Phase 2 LimphoStat-B
43 Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome Completed NCT01160666 Phase 2 Belimumab
44 Etanercept Therapy for Sjogren's Syndrome Completed NCT00001954 Phase 2 Etanercept
45 Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome Completed NCT00391924 Phase 2 Dehydroepiandrosterone
46 Pilot Study of Thalidomide to Treat Sjogren's Syndrome Completed NCT00001599 Phase 2 Thalidomide
47 Exploratory Study for Dry Mouth in Patients With Sjögren’s Syndrome Completed NCT00233363 Phase 2 Rebamipide
48 Rituximab Treatment in Sjogren's Syndrome Completed NCT00363350 Phase 1, Phase 2 rituximab (anti-CD20)
49 Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome Completed NCT00637793 Phase 2 NGX267;NGX267;NGX267;NGX267
50 DHEA Treatment for Sjogren's Syndrome Completed NCT00001598 Phase 2 Dehydroepiandrosterone

Search NIH Clinical Center for Sjogren Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: sjogren's syndrome

Genetic Tests for Sjogren Syndrome

Anatomical Context for Sjogren Syndrome

MalaCards organs/tissues related to Sjogren Syndrome:

41
Eye, Salivary Gland, Skin, Lung, Testes, Kidney, Thyroid

Publications for Sjogren Syndrome

Articles related to Sjogren Syndrome:

(show top 50) (show all 386)
# Title Authors Year
1
Survey of Ophthalmologists Regarding Practice Patterns for Dry Eye and Sjogren Syndrome. ( 29369232 )
2018
2
Sjogren Syndrome and Non-Sjogren Sicca Syndrome: Do They Affect the Vulva? ( 29406358 )
2018
3
Fibrillary Glomerulonephritis in a Patient with Sjogren's Syndrome. ( 29922524 )
2018
4
Primary Sjogren syndrome diagnosed simultaneously with localized amyloidosis of the lacrimal gland: A case report. ( 29879064 )
2018
5
Remission of Sjogren's Syndrome after Roux-en-Y Gastric Bypass for Morbid Obesity. ( 29248981 )
2018
6
Gastrointestinal and Hepatic Disease in Sjogren Syndrome. ( 29149922 )
2018
7
Upfront triple combination therapy-induced pulmonary edema in a case of pulmonary arterial hypertension associated with Sjogren's syndrome. ( 29276674 )
2018
8
Pleuritis associated with primary Sjogren syndrome. ( 29321929 )
2018
9
Unexplained cough: it is time to rule out Sjogren's syndrome. ( 29388084 )
2018
10
Hypokalemic Paralysis Due to Primary Sjogren Syndrome. ( 29911048 )
2018
11
Polyvalent immunoglobulins with vitamin D3 and vitamin B12 in the treatment of Sjogren's syndrome in a vegetarian with stomatitis, glossodynia, xerostomia, and elevated antinuclear antibodies: Case reporta8c. ( 29231165 )
2018
12
Clinical periodontal status and inflammatory cytokines in primary sjogren syndrome and rheumatoid artritis. ( 29752727 )
2018
13
Serum components and clinical efficacies of autologous serum eye drops in dry eye patients with active and inactive Sjogren syndrome. ( 29296554 )
2017
14
Thymic hyperplasia associated with primary Sjogren's syndrome cured by thymectomy. ( 28275496 )
2017
15
"Is it Sjogren's syndrome or burning mouth syndrome? Distinct pathoses with similar oral symptoms"-a commentary. ( 29217136 )
2017
16
Primary Sjogren's syndrome presenting as hypokalemic paralysis: A case series. ( 27853045 )
2017
17
Presence of enthesopathy in patients with primary Sjogren's syndrome: ultrasonographic study of a local cohort. ( 28646319 )
2017
18
Autoantibody to MDM2: A potential serological marker of primary Sjogren's syndrome. ( 28147328 )
2017
19
A Case of Renal Tubular Acidosis with Sjogren's Syndrome Showing Paradoxical Block of PTH Due to Severe Hypomagnesemia. ( 29062185 )
2017
20
Fibrillary Glomerulonephritis in Primary Sjogren's Syndrome: A Rare Cause of Renal Failure. ( 29196420 )
2017
21
Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome. ( 29200970 )
2017
22
Comparison of Tear Osmolarity in Rheumatoid Arthritis Patients With and Without Secondary Sjogren Syndrome. ( 28486313 )
2017
23
Antibodies against citrullinated alpha enolase peptides in primary Sjogren's syndrome. ( 28919520 )
2017
24
Ectopic germinal center and megalin defect in primary Sjogren syndrome with renal Fanconi syndrome. ( 28577559 )
2017
25
A Potential of sFasL in Preventing Gland Injury in Sjogren's Syndrome. ( 28326325 )
2017
26
Clinical Spectrum, Therapeutic Outcomes, and Prognostic Predictors in Sjogren's Syndrome-associated Neuropathy. ( 28904462 )
2017
27
Sjogren's syndrome complicating pancytopenia, cerebral hemorrhage, and damage in nervous system: A case report and literature review. ( 29390256 )
2017
28
Acute fibrinous and organizing pneumonia in a patient with Sjogren's syndrome. ( 27896062 )
2017
29
Elevated level of circulating CD4<sup>+</sup>Helios<sup>+</sup>FoxP3<sup>+</sup>cells in primary Sjogren's syndrome patients. ( 27538522 )
2017
30
Paeoniflorin ameliorates symptoms of experimental Sjogren's syndrome associated with down-regulating Cyr61 expression. ( 26630293 )
2016
31
The IL33/ST2 axis in Sjogren syndrome in relation to disease activity. ( 27097949 )
2016
32
Anesthetic management of patient with Sjogren's syndrome who underwent cesarean section: a case report. ( 27274376 )
2016
33
Mixed Connective Tissue Disorder Complicated by Polymyositis, Sjogren's Syndrome, Pleural Effusion and Pericarditis. ( 28083450 )
2016
34
Hypokalemic Paralysis in Sjogren's Syndrome Secondary to Renal Tubular Acidosis. ( 27731561 )
2016
35
Central pontine myelinolysis in Sjogren's syndrome with hypokalemia. ( 26929036 )
2016
36
Sialendoscopy-assisted treatment for chronic obstructive parotitis related to Sjogren syndrome. ( 28049607 )
2016
37
Sjogren's syndrome presenting as Hypokalemic paralysis due to distal renal tubular acidosis. ( 27728182 )
2016
38
TAFRO syndrome with primary Sjogren's syndrome. ( 27795506 )
2016
39
One patient with Sjogren's syndrome presenting schizophrenia-like symptoms. ( 27042076 )
2016
40
Serum 25-Hydroxyvitamin D3 and BAFF Levels Are Associated with Disease Activity in Primary Sjogren's Syndrome. ( 28074193 )
2016
41
Increased frequency of the PTPN22W* variant in primary Sjogren's Syndrome: Association with low type I IFN scores. ( 27810512 )
2016
42
Autonomic dysfunction in primary Sjogren's syndrome: a prospective cohort analysis of 154 Korean patients. ( 27017389 )
2016
43
Severity of dry eye syndrome is related to anti-dsDNA autoantibody in systemic lupus erythematosus patients without secondary Sjogren syndrome: A cross-sectional analysis. ( 27428227 )
2016
44
Investigation of novel autoantibodies in Sjogren's syndrome utilizing Sera from the Sjogren's international collaborative clinical alliance cohort. ( 25881294 )
2015
45
IL-22 receptor 1 is over-expressed in primary Sjogren's Syndrome and Sjogren-associated non-Hodgkin lymphomas and is regulated by IL-18. ( 25880879 )
2015
46
Microscopic polyangiitis associated with primary biliary cirrhosis, Sjogren's syndrome and Hashimoto's thyroiditis. ( 25758890 )
2015
47
Serotonin transporter gene polymorphisms: Relation with platelet serotonin level in patients with primary Sjogren's syndrome. ( 25903736 )
2015
48
Effect of Chinese herbal medicines for nourishing yin, supplementing qi, and activating blood on reproductive endocrine activity and immune functions in patients with primary Sjogren's syndrome. ( 26525549 )
2015
49
Contribution of dendritic cell immunoreceptor (DCIR) polymorphisms in susceptibility of systemic lupus erythematosus and primary Sjogren's syndrome. ( 26429306 )
2015
50
IL-36I+ axis is modulated in patients with primary Sjogren's Syndrome. ( 25902739 )
2015

Variations for Sjogren Syndrome

Expression for Sjogren Syndrome

Search GEO for disease gene expression data for Sjogren Syndrome.

Pathways for Sjogren Syndrome

Pathways related to Sjogren Syndrome according to KEGG:

37
# Name Kegg Source Accession
1 Toll-like receptor signaling pathway hsa04620
2 Jak-STAT signaling pathway hsa04630

Pathways related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.87 B2M CD79A FASLG TNFSF13B TNFSF4
2 10.28 FASLG TNFSF13B TNFSF4

GO Terms for Sjogren Syndrome

Cellular components related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 APOH B2M FASLG HSPG2 SIL1 TNFSF13B
2 ribonucleoprotein complex GO:1990904 8.8 SSB TRIM21 TROVE2

Biological processes related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor-mediated signaling pathway GO:0033209 9.33 FASLG TNFSF13B TNFSF4
2 negative regulation of angiogenesis GO:0016525 9.13 APOH FASLG HSPG2
3 positive regulation of T cell cytokine production GO:0002726 8.62 B2M TNFSF4

Molecular functions related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 8.8 FASLG TNFSF13B TNFSF4

Sources for Sjogren Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....